Tag: obesity market

Market News

Novo Nordisk Struggles: GLP-1 Market Challenges 2026

Novo Nordisk's stock has crashed 75% from its peak amid fierce competition, pricing squeezes, and a disappointing pipeline trial. Is...

26/02/2026

3 views

Read More

Altcoins

Novo Nordisk Stock Drops After Weight Loss Drug Trial Miss

Novo Nordisk's stock took a sharp hit after its promising next-gen weight loss drug CagriSema fell short against Eli Lilly's...

23/02/2026

3 views

Read More

Growth Picks

Buy Eli Lilly: Top GLP-1 Leader Amid Rising Competition

With competition closing in on the booming GLP-1 space, one pharma giant stands out as the clear frontrunner according to...

20/02/2026

2 views

Read More

Growth Picks

Three Smart Winners Beyond the AI Boom

As markets obsess over AI hardware giants, overlooked quality names in payroll, consulting, and healthcare are quietly building lasting value—could...

09/02/2026

3 views

Read More

Stocks

Eli Lilly Surges Ahead in GLP-1 Market as Novo Faces 2026 Decline

While both giants face U.S. pricing squeezes on weight-loss drugs, Eli Lilly just forecasted massive 2026 growth while Novo Nordisk...

04/02/2026

5 views

Read More

Altcoins

Novo Nordisk GLP-1 Pill: Pricing Pressures & 2026 Outlook

At JPMorgan 2026, Novo Nordisk's CEO warned of major price pressure on GLP-1 drugs this year, even as their new...

14/01/2026

4 views

Read More

Global Companies

Zealand Pharma’s Bold 2030 Plan Shakes Weight Loss Race

While Novo Nordisk shares are down 50% in 2025 and investors flock to Eli Lilly, a smaller Danish player just...

11/12/2025

2 views

Read More

Growth Picks

Eli Lilly Stock Soars: Why BofA Sees 22% More Upside

Bank of America just slapped a $1,286 price target on Eli Lilly — that’s 22% higher from here. The reason?...

02/12/2025

12 views

Read More

Growth Picks

Eli Lilly Slashes Zepbound Prices: Bullish for Investors?

Eli Lilly just dropped the cash price of Zepbound vials to $299-$399/month. The stock dipped 1% on the news, but...

01/12/2025

3 views

Read More

Global Companies

Novo Nordisk’s Bold Restructuring: Job Cuts and Strategic Shift

Novo Nordisk axes 9,000 jobs and slashes guidance as GLP-1 drugs face competition. Can the new CEO turn the tide...

10/09/2025

5 views

Read More